| Literature DB >> 31682895 |
David Anwanwan1, Santosh Kumar Singh1, Shriti Singh2, Varma Saikam3, Rajesh Singh4.
Abstract
Globally, liver cancer is the most frequent fatal malignancy; in the United States, it ranks fifth. Patients are often diagnosed with liver cancer in advanced stages, contributing to its poor prognosis. Of all liver cancer cases, >90% are hepatocellular carcinomas (HCCs) for which chemotherapy and immunotherapy are the best options for therapy. For liver cancer patients, new treatment options are necessary. Use of natural compounds and/or nanotechnology may provide patients with better outcomes with lower systemic toxicity and fewer side effects. Improved treatments can lead to better prognoses. Finally, in this review, we present some of the problems and current treatment options contributing to the poor outcomes for patients with liver cancer.Entities:
Keywords: Chemotherapeutics; Immunotherapy; Liver cancer; Natural compound
Mesh:
Substances:
Year: 2019 PMID: 31682895 PMCID: PMC6981221 DOI: 10.1016/j.bbcan.2019.188314
Source DB: PubMed Journal: Biochim Biophys Acta Rev Cancer ISSN: 0304-419X Impact factor: 10.680